Nationwide Rice Recall As FDA Issues Risk Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A nationwide recall of multiple rice products has been issued with the second-highest risk classification by the U.S. Food and Drug Administration (FDA).
NatureMills US Inc., a Texas-based company, issued a voluntary recall for numerous products on May 13 because of the undeclared presence of allergens, including milk and wheat.
The FDA issued a Class II risk classification for the recalled rice products on June 25.
Newsweek contacted NatureMills US Inc. for comment by email.
A stock image shows rice following NatureMills US Inc. issuing of a voluntary recall for various rice products.
A stock image shows rice following NatureMills US Inc. issuing of a voluntary recall for various rice products.
Silas Stein/picture-alliance/dpa/AP Images
Why It Matters
A Class II risk classification refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA.
Milk and wheat are among the nine major food allergens as set out in law. The others are eggs, fish, crustacean shellfish, tree nuts, peanuts, sesame and soybeans.
The FDA warned that people who have an allergy or severe sensitivity to milk and wheat "run the risk of serious or life-threatening allergic reactions if they consume these products."
Allergic reactions vary in severity from mild symptoms such as hives and lip swelling, to life-threatening complications such as anaphylaxis that may include fatal respiratory problems.
What To Know
The recalled rice products for which the FDA has issued Class II risk classifications are:
Sesame Rice Mix, 200g - 6712 units - undeclared milk - codes: SRMIXG / SRMXIIG / SRMVH - best-by dates: October 2025, January 2026 and June 2026.
Dal Garlic Rice Mix, 200g - 6712 units - undeclared milk and wheat - codes: DRMIXG / DRMXIIG / DRMVH - best-by dates: October 2025, January 2026, June 2026.
Moringa Rice Mix, 200g - undeclared wheat - 6712 units - codes: MRMIXG / MRMXIIG / MRMVH - best-by dates: October 2025, January 2026, June 2026.
Vallarai Rice Mix, 200g - undeclared wheat - 6712 units - codes: VRMIXG / VRMXIIG / VRMVH - best-by dates: October 2025, January 2026, June 2026.
Horsegram Rice Mix, 200g - undeclared wheat - 6712 units - codes: HRMIXG / HRMXIIG / HRMVH - best-by dates: October 2025, January 2026, June 2026.
Curry Leaf Rice Mix, 200g - undeclared wheat - 6712 units - codes: CRMIXG / CRMXIIG / CRMVIIH - best-by dates: June 2026, August 2026
The products were sold between December 1, 2023 and May 10, 2025 and were distributed throughout the US through the firm's website.
The FDA said that the recall was initiated after a routine internal audit found missing ingredients and allergen labels. It added that the problem was the result of an oversight in the packaging process, and that measures were taken to resolve the issue immediately.
As of May 13, no illnesses had been reported in connection with recalled products.
What People Are Saying
The FDA says on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food."
Dr. Sebastian Lighvani, the director of New York Allergy & Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods."
What Happens Next
The recall of the products is listed as ongoing, according to the FDA.
Consumers who purchased the items and are allergic to milk and wheat have been told not to consume them. They can contact NatureMills US Inc. for a full refund or replacement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
20 minutes ago
- The Hill
Duncan Hines parent Conagra Brands says it will phase out artificial colors
Conagra Brands, the parent company of Duncan Hines, Slim Jim and other brands, is the latest big food company to say it's discontinuing the use of artificial dyes. In a statement released Wednesday – the same day as a similar statement from Nestle – Chicago-based Conagra said it will remove artificial colors from its frozen foods by the end of this year. Conagra's frozen brands include Marie Callender's, Healthy Choice and Birds Eye. Conagra said it won't offer products containing artificial colors to K-12 schools by the beginning of the 2026-2027 school year, and it will work to discontinue artificial dyes across its entire portfolio by the end of 2027. Kraft Heinz and General Mills made similar pledges earlier this month. The federal government has stepped up its scrutiny of artificial colors in recent months. In January, days before President Donald Trump took office, the U.S. regulators banned the dye called Red 3 from the nation's food supply, nearly 35 years after it was barred from cosmetics because of potential cancer risk. In April, Trump's Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary said the agency would take steps to eliminate synthetic dyes by the end of 2026, largely by relying on voluntary efforts from the food industry. Many of Conagra's products already make a point of using natural dyes. On a jar of Vlasic kosher pickle spears, Conagra notes that they're colored with turmeric, not the synthetic Yellow 5. For the cheesy color in its frozen vegetable sides or its Orville Redenbacher popcorn, Conagra uses annatto, a plant extract. But some of Conagra's products still rely on synthetic colors. Duncan Hines' Comstock County Cherry pie filling uses Red 40, for example, while its Creamy Strawberries n' Cream Frosting uses both Red 40 and Yellow 5. Conagra's Swiss Miss Butterscotch pudding contains Yellow 6, Red 40 and Blue 1.
Yahoo
an hour ago
- Yahoo
Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas
PARIS, June 26, 2025--(BUSINESS WIRE)--Orano Med, a subsidiary of the Orano Group and a pioneer in radioligand therapies in oncology, today inaugurated the expansion of its main Research and Development Center located in Plano, Texas (USA). This strategic facility is dedicated to developing novel radiopharmaceuticals and conducting preclinical research focused on targeted alpha therapies using lead-212 (212Pb), an innovative and promising approach against various types of cancer. The site hosts the R&D teams of Orano Med as well as those of its subsidiary Macrocyclics, a manufacturer of customized chelating agents. With an investment of over $5 million, Orano Med has expanded its R&D Center by approximately 11,000 ft². The expansion includes around 5,000 ft² of new laboratory space, enabling the advancement of a growing pipeline and doubling the Good Manufacturing Practice (GMP) production capacity for early clinical trial supply. In addition, about 5,500 ft² of new office space has been added to accommodate the site's growing team, whose headcount has doubled over the past four years. Overall, this represents about a 50% increase in space compared to the pre-existing facility. Julien Torgue, Chief Scientific Officer of Orano Med, stated: "The expansion of our R&D center enhances our ability to develop lead-212-based radioligand therapies by giving our teams the resources they need to advance a growing pipeline of drug candidates through to the clinic. With an integrated platform, cutting-edge equipment and a focused scientific strategy, we are well positioned to support both our internal developments and collaborations with partners." Orano Med's R&D platform is fully integrated, combining cutting-edge equipment and a highly experienced team to advance the development of next-generation cancer therapies. The company can carry out the full range of preclinical development studies, including in vivo and Chemistry, Manufacturing and Controls (CMC) studies, onsite. Orano Med conducts both in-house research programs and collaborative developments with biotech and pharmaceutical partners. This integrated approach ensures a rapid and reliable transition from research to clinical phases. While the primary mission of the research and development center is therapeutic development, the facility also serves as production hub for lead-212 based drug candidates for early-stage clinical trials in the U.S. This expansion demonstrates Orano Med's strong commitment to innovation and leadership in the field of radioligand therapies, accelerating the development of new treatment options for patients worldwide. A celebration was held on-site with local teams and Orano Med's Executive Committee to mark this important milestone. During the event, Orano Med also unveiled the new name of the facility: Drug Development and Preclinical Unit (DDPU) – George de Hevesy Center Arnaud Lesegretain, President and Chief Executive Officer of Orano Med, added: "This expansion marks an important step in Orano Med's growth at our Plano site, which has played a key role since the inception of the company 15 years ago. It reinforces our world-class R&D capabilities in the U.S. and strengthens our ability to deliver innovative targeted alpha therapies by supporting early-stage development in a fully integrated environment." About Orano Med Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). AlphaMedix, its most advanced asset in clinical development for GEP-NETs tumors, received Breakthrough Designation from the FDA in 2024. The company is advancing several potential treatments using 212Pb combined with various targeting agents through clinical and preclinical studies. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US. It is expanding its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe and building a unique, independent, and fully integrated industrial platform to serve the needs of patients globally. For more information, please visit: About Orano As a recognized international leading operator in the field of nuclear materials, Orano delivers solutions to address present and future global energy and health challenges. Its expertise and mastery of cutting-edge technologies enable Orano to offer its customers high value-added products and services throughout the entire fuel cycle. Every day, the Orano group's 17,500 employees draw on their skills, unwavering dedication to safety and constant quest for innovation, with the commitment to develop know-how in the transformation and control of nuclear materials, for the climate and for a healthy and resource-efficient world, now and tomorrow. Orano, giving nuclear energy its full value. About Targeted Alpha Therapy Targeted alpha therapy (TAT) relies on a simple concept: combining the ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha-emitting radioisotopes. Alpha decay consists of the emission of a helium nucleus (alpha particle) together with very high linear energy transfer and a range emission of only few cell layers, resulting in irreparable double strand DNA breaks in cells adjacent only to area of alpha emission. This approach results in an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. As a result, alpha emitters are considered as the most powerful payloads to be found for targeted therapies. View source version on Contacts Mike SinclairHalsin Partnersmsinclair@
Yahoo
an hour ago
- Yahoo
FDA approves Gilead's twice-yearly injectable Yeztugo for PrEP
The US Food and Drug Administration (FDA) has approved Gilead Science's Yeztugo for the prevention of human immunodeficiency virus (HIV) infection. This is the first and only FDA-approved HIV pre-exposure prophylaxis (PrEP) option offering six months of protection. The approval was based on the Phase III PURPOSE 1 and PURPOSE 2 trials, which showed that more than 99% of participants remained HIV-negative on the twice-yearly injectable therapy. Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. Yeztugo will compete with Gilead's own oral PrEP therapies Truvada and Descovy, as well as ViiV Healthcare's Apretude, the only other injectable PrEP therapy available in the US. However, Apretude requires more frequent dosing than Yetzugo, as it is typically administered once every two months. The approval of Yeztugo is a momentous step in improving PrEP options available for people vulnerable to contracting HIV. Currently, the majority of PrEP therapies require daily oral administration. Key opinion leaders (KOLs) previously interviewed by leading data and analytics company GlobalData noted that there is often a psychosocial burden when taking daily PrEP due to stigma, and patients have concerns about others discovering their medication or adherence challenges. Yeztugo could address these key issues. However, KOLs noted that the cost of the drug could be a major barrier to uptake. Gilead has announced the US price of Yeztugo for PrEP at $28,218 per year for each patient. KOLs expressed doubts about whether insurance companies will cover the cost of this drug since generic versions of oral PrEP medications are widely available and much less expensive. Additionally, this situation may be exacerbated by the HIV funding cuts that have been proposed by US President Donald Trump's administration. Furthermore, PrEP usage has not been maximised across the US thus far. According to GlobalData epidemiologists, 437,425 people were on PrEP in the US in 2022, but this figure had the potential to be much higher. In the same year, only 36% of people in the US who met the Centers for Disease Control and Prevention's (CDC) eligibility criteria for PrEP were prescribed a form of PrEP. CDC data shows that vulnerable populations in the US are not yet using PrEP at rates that could end the transmission of the virus at the population level, with particular gaps for women, Black/African American, and Hispanic/Latino people. Increasing awareness and access will be an important element of reducing HIV through PrEP use and maximising Yetzugo's sales. Yeztugo is likely to be approved in other countries shortly, as Gilead has filed for regulatory approval in several markets, including the European Medicines Agency, where it is under accelerated review. "FDA approves Gilead's twice-yearly injectable Yeztugo for PrEP" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
